ArticleCureus2026
Prospective, Single-Arm, Investigator-Initiated Study to Evaluate Efficacy and Safety of Levocetirizine Hydrochloride 5 mg and Montelukast 10 mg (L-Montus) in Patients With Seasonal Allergic Rhinitis and Perennial Allergic Rhinitis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction To evaluate the efficacy and safety of a fixed-dose combination (FDC) of levocetirizine hydrochloride 5 mg and montelukast 10 mg (L-Montus) in the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis ( PAR ) among adult patients in India. Methods This was a prospective, single-arm, multicenter clinical study conducted across three clinical sites in India. A total of 200 patients aged 18 to 64 years with moderate-to-severe SAR were enrolled. All patients received once-daily oral doses of the FDC for eight weeks, with follow-up extending to 13 weeks. Symptom severity was assessed using validated tools: total nasal symptom score (TNSS), total ocular symptom score (TOSS), and night-time symptom score (NTSS). Safety and treatment adherence were monitored throughout the study. Statistical significance was evaluated using the Friedman and Wilcoxon signed-rank tests. Results At baseline, nasal symptoms such as sneezing (100%), rhinorrhea in 194 patients (97%), and nasal congestion in 191 patients (95.5%) were highly prevalent. By week eight, TNSS decreased from 6.74±2.28 to 0.86±1.11 (p=0.005), TOSS from 5.60±2.44 to 0.61±0.87 (p=0.005), and NTSS from 4.99±2.28 to 0.37±0.59 (p=0.005), demonstrating significant symptom relief. The treatment was well-tolerated, with only 14% (28) of patients reporting mild adverse events; no serious adverse events or discontinuations were observed. Conclusions The FDC of levocetirizine and montelukast (L-Montus) demonstrated robust efficacy in reducing nasal, ocular, and nocturnal symptoms associated with SAR, with a favorable safety and adherence profile. The dual mechanism of action targeting histaminergic and leukotriene pathways likely contributed to the comprehensive symptom control. These findings support the FDC as an effective first-line therapeutic option in the Indian SAR population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.